










                     
                
                 
                    
                 
             
              
           
               
         
             
              
             
                 
                 
              
               
                 
             




               
                
                   
                  
             
                 
                    
               
                     
                 
                  
               
               
                
               
                   
            
              
                  
             











            
                 





                  
      
 
            
           
              
             
             
         
                 
         
 
                    
                 
                  
 
                    
                  
               
           
 
                
           
             
             
             
                 
         
       
                 
         
   
             
                 
           
   
   
               
     
           
                 
Texas State‐based 
Amyotrophic Lateral Sclerosis (ALS) 
Surveillance Project Summary 
BACKGROUND RESULTS 
ALS, or Lou Gehrig’s disease, is a rare, difficult to diagnose 
neurological condition with no known cause or cure. 
Because ALS is a non‐notifiable disease, little is known 
about its incidence and prevalence in the U.S. To help 
learn more about ALS, the federal Agency for Toxic 
Substances and Disease Registry (ATSDR) maintains the 
National ALS Registry (Registry).1,2 The Registry identifies 
ALS cases using national administrative databases, 
including those from Medicaid, Medicare, and the Veterans 
Health Administration and Veterans Benefits 
Administration, and by patient self‐enrollment through a 
web portal. ATSDR funded McKing Consulting Corporation 
(McKing) to complete surveillance projects to gather 
reliable and timely data to describe the incidence and 
demographic characteristics of ALS and to assist ATSDR in 
evaluating the completeness of the Registry. Surveillance 
projects were conducted in three states (Florida, New 
Jersey, and Texas) and in eight metropolitan areas (Atlanta, 
Baltimore, Chicago, Detroit, Las Vegas, Los Angeles, 
Philadelphia, and San Francisco). This summary describes 
the Texas project. 
METHODS 
McKing partnered with the Texas Department of State 
Health Services (DSHS) to conduct the project. All 
neurologists practicing in the state of Texas were asked if 
they diagnosed or provided care for ALS patients. Emphasis 
was placed on neurologists specializing in the 
diagnosis/care of persons with ALS who practice at referral 
centers that typically see more than 50 patients per year. 
Neurologists were asked to submit one‐page case reports 
for ALS patients under the doctor’s care who were alive at 
some point between January 1, 2009 and December 31, 
2011. A medical record verification form (MRVF) and an 
electromyogram (EMG) report were requested for a sample 
of cases and reviewed by an independent consulting 
neurologist to confirm ALS diagnosis. Death data were 
reviewed to identify additional cases, and attempts were 
made to obtain case reports for decedents that were not 
already reported. Compensation was offered to 
neurologists for completed forms. No patients were 
contacted. This project was approved by the Centers for 
Disease Control and Prevention Institutional Review Board 
(IRB) and the Texas DSHS IRB. 
►	 Twenty‐five percent (204/829) of neurologists indicated 
that they diagnosed and/or cared for ALS patients and 
54% (110/204) of those neurologists reported cases 
(Table 1). 
Table 1: Recruitment and Participation of Neurologists in Texas 
n %* 
All neurologists 829 100.0 
Diagnosed/care for ALS patients in 
reporting period 
204 24.6 
Reported cases 110 13.3 
Did not report cases 94 11.3 
Diagnose/care for ALS patients, not in 
reporting period 
67 8.1 
Will not diagnose/care for ALS patients 503 60.7 
Unknown 54 6.5 
Other physicians reporting cases 1 n/a 
*Does not add up to 100% due to rounding. 
►	 A total of 1,670 case reports were received; 1,423 
were unique cases. 
►	 Ninety‐two percent (1,305/1,423) of cases were 
reported as “definite,” “probable,” or “probable‐lab 
supported” according to the El Escorial criteria.3 
Ninety‐four percent (217/232) of the requested MRVFs 
were received; 76% (165/217) were classified as 
“definite,” “probable,” or “probable‐lab supported,” 
and 24% (52/216) were classified as “possible” or “not 
classifiable” by the consulting neurologist. 
►	 Seventy‐nine percent of cases were 50 years of age or 
older at diagnosis, 56% were male, 80% were white, 
and 74% were not Hispanic or Latino (Table 2). 
►	 Of the 1,245 cases for whom data were available, 50% 
had symptoms for 12 months or less before diagnosis. 
Ninety percent of the 1,245 cases were diagnosed 
within 36 months of having symptoms. 
►	 Forty percent (563/1,423) of cases had only federal 
payers [Medicare, Medicaid, Veterans Affairs (VA)], 
39% (554/1,423) had only non‐federal payers (HMO, 
private insurance, self‐pay, or other), and 21% 





              
                 
                 
 
                  
             
 
 
              
                   
                 
              
 
                  
                      
               
 
                  
                   
              













                
             
             
           
       
 
              
             
                 
                  
                   
   
 
            
             
       
 
              
           
           
                 
           
 
              
               
 
 
                
              
               
             
         
 
 
            
             
             
         
       
                
           
 
                    
               
             
             
           
              
       
 
       
                    
           
 
                 
     
          
   
         
           
           
           
           
           
       
 
       
       
 
         
           
         
       
       
 
       
             
       
                 
                 
                                 
                             
Table 2: Demographic Characteristics of All Reported ALS Cases 
in Texas, n=1,423 
Demographic Characteristic n %* 
Age (years) 
Under 40 82 5.7 
40 – 49 201 14.1 
50 – 59 351 24.7 
60 – 69 426 29.9 
70 – 79 276 19.4 
80 or older 76 5.3 
Unknown 11 0.8 
Sex 
Male 796 55.9 
Female 627 44.1 
Race 
White alone 1135 79.8 
Black/African American alone 93 6.5 
Asian alone 21 1.5 
Other** 1 0.0 
Unknown 173 12.2 
Ethnicity 
Hispanic 213 15.0 
Not Hispanic or Latino 1053 74.0 
Unknown 157 11.0 
*May not add up to 100% due to rounding. 
**Those with multiple races are listed here. 
DISCUSSION 
►	 One‐quarter of neurologists diagnosed or cared for 
patients with ALS during the reporting period and a 
little more than one‐half of them reported cases. 
►	 Most of the ALS referral centers in the state 
participated and submitted the majority of case 
reports. 
►	 Some non‐referral center practices and the VA 
hospitals and clinics had cases to report but declined to 
participate. However, it is unclear if providers at these 
practices would have reported unique ALS cases. 
►	 Many unique names were identified in the death data 
that were not reported to the project. It is unknown if 
any of these individuals were true ALS cases. 
►	 The expected number of cases in the three‐year period 
was 2,0124,5 and only 1,423 cases were reported to the 
project. Incidence rates were not calculated because 








►	 The geographic distribution of ALS cases across the 
state reflected the Texas population distribution with 
approximately two‐thirds of reported cases residing in 
Texas’ main metropolitan areas (Austin, Houston, 
Dallas, and San Antonio). 
►	 Although the major metropolitan areas have large 
specialty centers, there are many rural providers 
spread throughout the state who each see a small 
number of patients. It may be difficult for persons 
with ALS to travel from remote rural locations to the 
metropolitan areas. 
►	 Lessons learned regarding physician recruitment that 
may prove helpful in replicating similar surveillance 
efforts include the following: 
	 Creating targeted phone call lists, sending faxes 
immediately followed by phone calls, and 
conducting on‐site visits appeared to increase 
visibility of the project, but did not seem to 
increase participation of non‐referral center sites. 
	 Garnering the support and participation of major 
ALS referral centers in the catchment area was 
imperative. 
►	 The results of this project demonstrate that active
 
case ascertainment is expensive and laborious. In
 
addition, not all neurologists are willing to provide
 
case reports, which supports the methodology used
 
by the National ALS Registry.
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